{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:52:01Z","timestamp":1781779921321,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.mayocpiqo.2025.100622","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:30:28Z","timestamp":1747027828000},"page":"100622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longer Drug Retention of Interleukin-12\/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis"],"prefix":"10.1016","volume":"9","author":[{"given":"Godehard A.","family":"Scholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Papagiannoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Blapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Yawalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Amsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocpiqo.2025.100622_bib1","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2025.100622_bib2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis (PsA) core domain set: A report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2025.100622_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"77","key":"10.1016\/j.mayocpiqo.2025.100622_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10235","key":"10.1016\/j.mayocpiqo.2025.100622_bib8","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"10201","key":"10.1016\/j.mayocpiqo.2025.100622_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (Eclipse): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100622_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.42758","article-title":"Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis: results from the European spondyloarthritis research collaboration network","volume":"76","author":"Hellamand","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100622_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (Biopure)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mayocpiqo.2025.100622_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fmed.2020.00288","article-title":"Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis","volume":"7","author":"Klavdianou","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001519","article-title":"Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study","volume":"7","author":"Ramonda","year":"2021","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2025.100622_bib15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","article-title":"Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results","volume":"80","author":"Smolen","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.55563\/clinexprheumatol\/1sx5yk","article-title":"Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis","volume":"40","author":"Eviatar","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9596","key":"10.1016\/j.mayocpiqo.2025.100622_bib19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2021-221307","article-title":"EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology","volume":"81","author":"Courvoisier","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100622_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100622_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2025.100622_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2025.100622_bib27","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1016\/j.mayocpiqo.2025.100622_bib28","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2025.100622_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100622_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100622_bib33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician\u2019s global assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"J Public Health Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2025.100622_bib35","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2025.100622_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11926-018-0744-2","article-title":"Gender differences in axial spondyloarthritis: women are not so lucky","volume":"20","author":"Rusman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2025.100622_bib38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2025.100622_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"10.1016\/j.mayocpiqo.2025.100622_bib40","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2025.100622_bib41","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2025.100622_bib42","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2025.100622_bib43","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1093\/rheumatology\/keab329","article-title":"\u2018Too much of a good thing\u2019: can network meta-analysis guide treatment decision-making in psoriatic arthritis?","volume":"60","author":"Marzo-Ortega","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.mayocpiqo.2025.100622_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why Inhibition of IL-23 Lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.mayocpiqo.2025.100622_bib45","article-title":"IL-23 inhibition in ankylosing spondylitis: where did it go wrong?","volume":"11","author":"Baeten","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2025.100622_bib46","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2025.100622_bib47","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/kex323","article-title":"Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort","volume":"56","author":"Tillett","year":"2017","journal-title":"Rheumatology (Oxford)"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454825000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454825000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T07:12:19Z","timestamp":1749453139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454825000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2542454825000335"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2025.100622","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longer Drug Retention of Interleukin-12\/23 or Interleukin-17 Inhibitors Compared With TNF Inhibitors in Female Patients With TNF Inhibitor-Experienced Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2025.100622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}],"article-number":"100622"}}